Coherus BioSciences Gross Profit 2013-2021 | CHRS

Coherus BioSciences gross profit from 2013 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Coherus BioSciences Annual Gross Profit
(Millions of US $)
2020 $438
2019 $339
2018 $
2017 $2
2016 $190
2015 $30
2014 $31
2013 $3
2012 $2
2011 $999
2010 $1,015
2009 $1,024
2008 $1,148
2007 $1,302
2006 $861
2005 $841
Coherus BioSciences Quarterly Gross Profit
(Millions of US $)
2021-06-30 $71
2021-03-31 $76
2020-12-31 $99
2020-09-30 $105
2020-06-30 $126
2020-03-31 $109
2019-12-31 $116
2019-09-30 $105
2019-06-30 $83
2019-03-31 $35
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31 $0
2017-09-30
2017-06-30 $1
2017-03-31 $0
2016-12-31 $1
2016-09-30 $163
2016-06-30 $14
2016-03-31 $12
2015-12-31 $10
2015-09-30 $7
2015-06-30 $7
2015-03-31 $6
2014-12-31 $6
2014-09-30 $16
2014-06-30 $5
2014-03-31 $4
2013-12-31
2013-09-30 $1
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.300B $0.476B
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00